Skip to main content

Dentsply Sirona Value Stock - Dividend - Research Selection

Dentsply sirona

ISIN: US24906P1093 , WKN: A2AF0E

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials. In addition, it provides dental technology products, including dental implants and related scanning equipment, treatment software, and orthodontic appliances for dental practitioners and specialist, and dental laboratories; and dental equipment, such as treatment centers, imaging equipment, and computer aided design and machining systems for dental practitioners and laboratories. Further, the company offers healthcare consumable products, such as urology catheters, various surgical products, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers to dentists, dental hygienists, dental assistants, dental laboratories, and dental schools; and urology products directly to patients, as well as through distributors to urologists, urology nurses, and general practitioners. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in York, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


These Analysts Boost Their Forecasts On Dentsply Sirona Following Q4 Earnings

2026-03-02
Dentsply Sirona (XRAY) reported mixed Q4 results, missing earnings but beating sales estimates. FY2026 projections below market expectations.

Mizuho Maintains Neutral on Dentsply Sirona, Raises Price Target to $16

2026-03-02
Mizuho analyst Steven Valiquette maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and raises the price target from $14 to $16.

Barrington Research Maintains Outperform on Dentsply Sirona, Raises Price Target to $17

2026-03-02
Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and raises the price target from $14 to $17.

Dentsply (XRAY) Rebounds 15.5% on Share Buyback

2026-02-28
We recently published 10 Stocks Ending February With a Bang. Dentsply Sirona Inc. (NASDAQ:XRAY) was one of the best performers on Friday. Dentsply bounced back by 15.50 percent on Friday to finish at $14.68 apiece, as investor sentiment was boosted by announcements of a share repurchase program, which overshadowed the termination of its quarterly dividends. […]

Dividend Champion, Contender, And Challenger Highlights: Week Of March 1

2026-02-27

Why Are Dentsply Sirona (XRAY) Shares Soaring Today

2026-02-27
Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) jumped 13.4% in the afternoon session after the company reported mixed fourth-quarter results, with investors seemingly focusing on a revenue beat while overlooking a weak outlook for the upcoming year.

DENTSPLY SIRONA Q4 Earnings Call Highlights

2026-02-27
DENTSPLY SIRONA (NASDAQ:XRAY) executives told investors on the company’s fourth-quarter 2025 earnings call that 2025 marked a year of organizational changes and that management is now focused on executing a 24-month “Return-to-Growth” action plan in 2026, centered on customer focus, accelerated inno

Does Dividend Elimination And R&D Pivot Change The Bull Case For DENTSPLY SIRONA (XRAY)?

2026-02-27
DENTSPLY SIRONA has reported its fourth quarter and full-year 2025 results, showing quarterly sales of US$961 million, a reduced net loss of US$146 million, and significant non-cash impairment charges tied to weaker volumes in key U.S. equipment and implant categories. Alongside new 2026 sales guidance of US$3.5–3.6 billion, the company is reallocating capital by eliminating its dividend, increasing R&D investment, and emphasizing debt reduction and share repurchases as part of its...

Bank, Private-Equity Stock Rout Deepens As AI Fears Mount: What's Moving Markets Friday?

2026-02-27
A sharp banking selloff gripped Wall Street on Friday, compounding a week dominated by concerns over artificial intelligence-driven economic disruption. Hotter-than-expected producer price data added pressure, clouding the Federal Reserve's rate-cut path.

XRAY Stock Gains Despite Q4 Earnings Miss on Restructuring Initiative

2026-02-27
XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.